ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Until recently, the UN was on track to meet its target of ending AIDS as a public health threat by 2030. But with the U.S.

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Standard Group Plc HQ Office, The Standard Group Center,Mombasa Road. P.O Box 30080-00100,Nairobi, Kenya. Telephone number: 0203222111, 0719012111 ...

The researchers plan to continue testing their work with medications used in combination therapies along with lamivudine, as most of these treatments involve a cocktail of two or more drugs. Because ...

Thanks to major medical advances, HIV often is a manageable long-term disease. Here’s what you need to know about treatment to lead a long, healthy life.

The key to HIV treatment as prevention is meds you’ll take daily. The regimen itself is called antiretroviral therapy, or ART. It’s ideal to start as soon as you’ve been diagnosed.

Lenacapavir's cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month.

The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.

Lenacapavir’s cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month.

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with HIV without preliminary drug resistance testing in a phase 4 trial.